



INTERIM REPORT 2021



MODERN DENTAL GROUP LIMITED 現代牙科集團有限公司

(a company incorporated in the Cayman Islands with limited liability)

Stock code: 3600







CONTENTS

Management Discussion and Analysis	2
Other Information	21
Interim Condensed Consolidated Statement of Profit or Loss	28
Interim Condensed Consolidated Statement of Comprehensive Income	29
Interim Condensed Consolidated Statement of Financial Position	30
Interim Condensed Consolidated Statement of Changes in Equity	32
Interim Condensed Consolidated Statement of Cash Flows	34
Notes to the Interim Condensed Consolidated Financial Statements	36
Corporate Information	61



MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

Modern Dental Group Limited (the “**Company**”, stock code: 3600) and its subsidiaries (which are collectively referred to as the “**Group**” or “**Modern Dental**”) is a leading global dental prosthetic device provider with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorised into three product lines: (i) fixed prosthetic devices such as crowns and bridges; (ii) removable prosthetic devices such as removable dentures; and (iii) others such as orthodontic devices (including clear aligner), sports guards and anti-snoring devices, raw materials, dental equipment and the services of educational events and seminars rendered.

MANAGEMENT DISCUSSION AND ANALYSIS

For the first half of 2021, the Group capitalised on the industry-wide pent-up demand for dental products and services as a result of significant tailwinds generated by an increase in spending by consumers on specialty dental treatments and tailwinds driven by the digitalisation of, and the adoption of intra-oral scanners in, the dental market. Furthermore, the Group benefited from a significant increase in new clients in certain key markets, as the lasting effects of the pandemic continued to disproportionately affect our smaller and mid-scaled competitors leading to, in the Group's view, an increase in market share in the applicable markets. As the global leader in the dental prosthetics industry, the Group is in an ideal position to take advantage of the aforementioned trends. The Group's results represent a strong and continued recovery in the dental market and solid execution across each of the Group's markets operationally and financially, as most of the Group's key and applicable metrics have improved significantly beyond pre-pandemic levels illustrating the Group's competitiveness in the industry, ability to thrive under uncertain business conditions and close relationship with its clients and customers. To put it simply, the Group refused to stand still during the first half of 2021 as it manoeuvres its way out of, and emerges from, the pandemic in a stronger and improved form. Notwithstanding the resurgence of COVID-19 in certain markets, the Group is confident that the underlying fundamentals of its business are solid and that it is well-positioned to capture further opportunities going forward.

RESULTS HIGHLIGHTS

- The Revenue for the six months ended 30 June 2021 was approximately HK\$1,481,225,000 (six months ended 30 June 2020: HK\$897,223,000), representing an increase of approximately HK\$584,002,000 or 65.1% as compared with that of the six months ended 30 June 2020.
- The Gross Profit Margin for the six months ended 30 June 2021 was approximately 52.7% (six months ended 30 June 2020: 46.1%). Gross profit for the six months ended 30 June 2021 was approximately HK\$780,240,000, representing an increase of approximately HK\$366,217,000 or 88.5% as compared with that of the six months ended 30 June 2020.
- The Group's EBITDA for the six months ended 30 June 2021 was approximately HK\$375,195,000 (six months ended 30 June 2020: HK\$107,491,000), representing an increase of approximately HK\$267,704,000 or 249.0%.
- The Group's Net Profit and Profit from core operations for the six months ended 30 June 2021 were approximately HK\$240,005,000 and HK\$240,005,000 (six months ended 30 June 2020: Net Loss and Profit from core operations were approximately HK\$139,502,000, which included an one-off non-cash impairment of goodwill for our North America region of approximately HK\$150,132,000, and HK\$14,518,000, respectively), representing an increase of approximately HK\$379,507,000 and HK\$225,487,000, respectively.
- Basic earnings per share for the six months ended 30 June 2021 amounted to HK25.06 cents (six months ended 30 June 2020: basic loss per share amounted to HK14.48 cents).
- In celebration of the Group's 35th anniversary and in special recognition of Chan Kwun Fung's (former Chairman) and Chan Kwun Pan's (former Vice-Chairman) extraordinary contribution to the Group for their decades of commitment, dedication and professionalism, the board of directors (the "**Board**" or the "**Directors**") declared a special dividend of HK5.0 cents (six months ended 30 June 2020: Nil) per ordinary share, together with an interim dividend of HK7.5 cents (six months ended 30 June 2020: Nil) per ordinary share for the six months ended 30 June 2021. The interim dividend and special dividend will be payable on Friday, 15 October 2021 to shareholders of the Company (the "**Shareholders**") whose names appear on the Register of Members of the Company on Wednesday, 29 September 2021.

MANAGEMENT DISCUSSION AND ANALYSIS

The following table sets forth summary of key financial results for the six months ended 30 June 2021, 2020 and 2019.

	Six months ended 30 June				
	2021	2020	2019	Changes	Changes
	(unaudited) HK\$'000	(unaudited) HK\$'000	(unaudited) HK\$'000	2021v2020 %	2021v2019 %
Revenue	1,481,225	897,223	1,191,378	65.1%	24.3%
Gross Profit	780,240	414,023	570,023	88.5%	36.9%
Gross Profit Margin (%)	52.7%	46.1%	47.8%	14.3%	10.3%
EBITDA	375,195	107,491	194,262	249.0%	93.1%
EBITDA Margin (%)	25.3%	12.0%	16.3%	110.8%	55.2%
Net Profit/(loss)	240,005	(139,502)	86,960	N/A	176.0%
Net Profit/(loss) Margin (%)	16.2%	-15.5%	7.3%	N/A	121.9%
Profit from core operations	240,005	14,518	88,557	1,553.2%	171.0%
Profit from core operations Margin (%)	16.2%	1.6%	7.4%	912.5%	118.9%

Further highlights:

- For the six months ended 30 June 2021, the Group's revenue from its European market increased by 66.9%, its North American market increased by 50.5%, its Greater China market increased by 74.5% (in particular, Mainland China increased by 113.2%) and its Australian market increased by 71.2%, in each case, compared with the six months ended 30 June 2020.
- For the six months ended 30 June 2021, the Group's digital solution cases (overseas and domestic) that are produced from its Mainland China production facilities (which, for the avoidance of doubt, does not include digital solution cases produced in the Group's non-Mainland China production facilities or overseas/satellite dental laboratories) increased to approximately 117,589 cases reflecting an increase of 200.7% as compared with the same period in 2020 (approximately 39,100 cases) as a result of our clients' increased adoption of intra-oral scanners.


MANAGEMENT DISCUSSION AND ANALYSIS

PRODUCT CATEGORY

The figures below set forth the breakdown of revenue (in thousand Hong Kong dollars and percentage) and sales volume (in number of cases and percentage) by product category for the six months ended 30 June 2021 and 2020 respectively:


BREAKDOWN OF REVENUE

(HK\$'000 and %)



BREAKDOWN OF SALES VOLUME

(no. of cases and %)



* Raw materials revenue, dental equipment revenue and services revenue are subtracted from the Group's revenue.

MANAGEMENT DISCUSSION AND ANALYSIS

FIXED PROSTHETIC DEVICES

Our fixed prosthetic devices, including crowns and bridges, are used for restorative dental procedures. Crowns are fixed replacements for a single tooth while bridge treatments permanently replace several adjacent teeth.

During the period under review, the fixed prosthetic devices business segment recorded a revenue of approximately HK\$982,020,000 representing an increase of approximately HK\$355,845,000 as compared with the six months ended 30 June 2020. This business segment accounted for approximately 70.5% of the Group's total revenue as compared with approximately 72.8% in the six months ended 30 June 2020.

REMOVABLE PROSTHETIC DEVICES

Our removable prosthetic devices primarily comprise dentures. As prostheses are used to replace natural teeth, they must provide functional biting and chewing surfaces and must also appear and feel natural.

During the period under review, the removable prosthetic devices business segment recorded a revenue of approximately HK\$259,626,000, representing an increase of approximately HK\$97,024,000 as compared with the six months ended 30 June 2020. This business segment accounted for approximately 18.6% of the Group's total revenue as compared with approximately 18.9% in the six months ended 30 June 2020.

OTHER DEVICES

Other devices include orthodontic devices, anti-snoring devices, and sports guards.

During the period under review, the other devices business segment recorded a revenue of approximately HK\$152,093,000, representing an increase of approximately HK\$80,980,000 as compared with the six months ended 30 June 2020. This business segment accounting for approximately 10.9% of the Group's total revenue as compared with approximately 8.3% in the six months ended 30 June 2020. Including in this business segment, the sales of TrioClear (our own aligner) is approximately HK\$10,561,000 (six months ended 30 June 2020: HK\$695,000).

MANAGEMENT DISCUSSION AND ANALYSIS

PRODUCT CATEGORY

The following table sets forth the breakdown of sales volume, revenue, and average selling price ("ASP") by product category for the six months ended 30 June 2021 and 2020 respectively:


Product category	Six months ended 30 June					
	2021			2020		
	Sales Volume (number of cases)	Revenue (HK\$'000)	ASP (HK\$ per case)	Sales Volume (number of cases)	Revenue (HK\$'000)	ASP (HK\$ per case)
Fixed prosthetic devices	566,138	982,020	1,735	376,988	626,175	1,661
Removable prosthetic devices	216,188	259,626	1,201	139,752	162,602	1,164
Other devices*	236,340	152,093	644	127,009	71,113	560
Total	1,018,666	1,393,739	1,368	643,749	859,890	1,336

* The raw materials revenue, the dental equipment revenue and the services revenue are subtracted from the Group's revenue.


SALES VOLUME AND AVERAGE SELLING PRICE

For the six months ended 30 June 2021, the sales volume and ASP of the Group's products across its markets were 1,018,666 cases (six months ended 30 June 2020: 643,749 cases) and HK\$1,368 per case (six months ended 30 June 2020: HK\$1,336 per case), representing an increase of 58.2% and 2.4%, respectively.

For the six months ended 30 June 2021, the Group's digital solution cases (overseas and domestic) that are produced from its Mainland China production facilities (which, for the avoidance of doubt, does not include digital solution cases produced in the Group's non-Mainland China production facilities or overseas/satellite dental laboratories) increased to approximately 117,589 cases reflecting an increase of 200.7% as compared with the same period in 2020 (approximately 39,100 cases) as a result of our clients' increased adoption of intra-oral scanners.



MANAGEMENT DISCUSSION AND ANALYSIS



The trademarks represent reputable brands and logos associated with such brands in each country or region; are widely recognised by practitioners in the dental industry; and are registered, where appropriate, with minimal renewal costs.

GEOGRAPHIC MARKET

By leveraging on our sales and distribution network, we achieved a leading position in the dental prosthetics industry across Europe, North America, Greater China, Australia, and other countries. The following table sets forth a breakdown of the revenue generated from the aforesaid markets in their respective original currency against HK\$ for the six months ended 30 June 2021 and 2020, respectively:

Market	Original currency	Six months ended 30 June					
		2021		2020		Changes in currency (%)	Organic growth rate (%)
		Conversion rate # (Original currency per HK\$)	Revenue (HK\$'000)	Conversion rate # (Original currency per HK\$)	Revenue (HK\$'000)		
Europe*	EUR	9.35	596,970	8.55	363,699	9.4%	50.1%
North America*	US\$	7.75	358,795	7.75	240,286	—	49.3%
Greater China**	RMB	1.20	304,613	1.10	174,442	9.1%	60.1%
Australia***	AUD	5.99	116,271	5.10	73,957	17.5%	33.9%
Others			17,090		7,506		
Total			1,393,739		859,890		

* The dental equipment revenue is subtracted from the European and the North American revenue.

** The raw materials and the dental equipment revenue are subtracted from the Greater China revenue.

*** Our Australian market includes both Australia and New Zealand. The services revenue and the dental equipment revenue are subtracted from the Australian revenue.

The conversion rate shall not be taken as a representation that respective original currency could actually be converted into HK\$ at that rate, or at all.

MANAGEMENT DISCUSSION AND ANALYSIS

EUROPE

The revenue generated from sales in the European markets, including France, Germany, the Netherlands, Belgium, Denmark, Sweden, Norway, Spain, the United Kingdom and other European countries, accounted for the largest portion of our revenue for the period under review.

Our Europe region experienced unprecedented demand for its products and services for the first half of 2021 as revenues significantly exceeded pre-pandemic levels of 2019 (for the same period). Significant tailwinds were generated by an increase in spending by consumers on specialty dental treatments and by digitalization of, and adoption of intra-oral scanners in, the dental market. In particular, sales of intra-oral scanners in the Europe region increased by 81.4% during this period.

The European region benefited from a significant increase in new clients as the lasting effects of the pandemic continued to disproportionately affect our smaller and mid-scaled competitors leading to, in the Group's view, a material increase in market share in this region. As the leading dental prosthetics supplier in Europe, the Group is in an ideal position to take advantage of the aforementioned trends.

The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalisation trend of the dental industry. The Group is committed and would continue to equip ourselves to provide the state-of-the art digital solutions offering to the dental community in the market.

During the period under review, the European market recorded a revenue of approximately HK\$596,970,000, representing an increase of approximately HK\$233,271,000 as compared with six months ended 30 June 2020. Together with the sales of dental equipment of approximately HK\$45,220,000, this geographic market accounted for 43.4 % of the Group's total revenue as compared with approximately 42.9% for the six months ended 30 June 2020. The increase of revenue from the European market was attributable to increase in the sales orders volumes, appreciation of Euro against HK\$ of 9.4% and increase in sales of dental equipment compared with the six months ended 30 June 2020.

NORTH AMERICA

The revenue generated from sales in the North American market, including the United States and Canada, represented the second largest portion of our revenue in the period under review.

MicroDental Laboratories, Inc. and its subsidiaries ("**MicroDental Group**") contributed approximately HK\$286,072,000 (six months ended 30 June 2020: HK\$193,520,000) to the Group's revenue, approximately HK\$40,768,000 (six months ended 30 June 2020: HK\$6,176,000) to the Group's Adjusted EBITDA; approximately HK\$25,667,000 of profit (six months ended 30 June 2020: HK\$161,105,000 of loss) to the Group's profit; and approximately HK\$25,667,000 of profit from core operations (six months ended 30 June 2020: HK\$10,713,000 of loss) to the Group's profit from core operations for the six months ended 30 June 2021. The profit of approximately HK\$25,667,000 (six months ended 30 June 2020: loss of HK\$161,105,000) for the six months ended 30 June 2021 included (i) no one-off non-cash impairment loss of goodwill (six months ended 30 June 2020: HK\$150,132,000); and (ii) non-cash depreciation and amortisation of approximately HK\$14,381,000 (six months ended 30 June 2020: HK\$15,288,000).

The Group is focused on ensuring solid execution of its North American business operationally and financially. We continue to implement substantial cost controls while maintaining appropriate operational and critical customer centric support service levels. Due to general softness and constraints in the North American market as a result of COVID-19-related lockdown measures and weather-related disruptions in February 2021, revenue from our North American market was slightly affected. However, during the second quarter of 2021, the Group experienced an increase in demand for its products as a direct result of the re-opening of the North American economy, pent-up demand and certain fiscal policies and fiscal stimulus adopted by the new administration.

MANAGEMENT DISCUSSION AND ANALYSIS

For the first half of 2021, our clients' interest surrounding digital dentistry continued to increase. With our centralised digital workflows and network oversight over our wide coverage of production units within the region, we are well positioned to support the customers needs through their digitalization journey, focusing on leveraging efficiencies and providing an enhanced customer experience throughout the network.

During the period under review, the North American market recorded a revenue of approximately HK\$358,795,000, representing an increase of approximately HK\$118,509,000 as compared with the six months ended 30 June 2020. Together with the sales of dental equipment of approximately HK\$2,833,000, this geographic market accounted for approximately 24.4% of the Group's total revenue as compared with approximately 26.8% in the six months ended 30 June 2020. The increase of revenue from the North American market was largely attributable to increase in the sales orders volumes and increase in sales of dental equipment.

GREATER CHINA

Our Greater China market comprises of Mainland China, Hong Kong and Macau. The revenue generated from sales in the Greater China market accounted for the third largest portion of our revenue in the period under review. Our Greater China region experienced unprecedented demand for its products and services for the first half of 2021 as revenues significantly exceeded pre-pandemic levels of 2019 (for the same period). In particular, revenues of the Mainland China market for the first half of 2021 increased by 113.2% compared with the first half of 2020 and by 39.4% compared with the first half of 2019.

Given the significant rise in the living standards in Greater China over the years, people have become increasingly aware of the importance of oral health, which benefits the custom-made dental prosthetics domestic sales market. We offer comparatively higher prices for products with premium quality in Greater China, which appeal to the population that has a strong demand for higher quality products. With our new production facilities in Dongguan at full operation, and new products addressing the mid-market segment of the dental industry, we expect to further consolidate our leading status in the Greater China market. The Mainland China market benefited from a significant increase in clients as the lasting effects of the pandemic continued to disproportionately affect our smaller and mid-scaled competitors leading to, in the Group's view, a material increase in market share in this region.

The management is cautiously optimistic on the long-term prospect of the Greater China region and is committed to support the development of the dental community in the region for long-term by (i) increasing focus on our educational platforms, Center of Dental Education and Pure Dental (“普潔”), which strategically increased the number of online education webinars offered by various leading industry experts to capture the less busy schedule of our dentists customers for educations and promotions of our latest state-of-the art innovative solutions and products offering; (ii) continuing to expand the depth and width of our products portfolios offering, such as adding mid-end products in the Mainland China and adding implants and clear aligners products in Hong Kong and Macau; and (iii) launching of our own dental digital platform in Hong Kong.

During the period under review, the Greater China market recorded a revenue of approximately HK\$304,613,000, representing an increase of approximately HK\$130,171,000 as compared with six months ended 30 June 2020. Together with the sales of raw materials and dental equipment of approximately HK\$27,264,000, this geographic market accounted for approximately 22.4% of the Group's total revenue as compared with approximately 21.2% in the six months ended 30 June 2020. The increase of revenue from the Greater China market was largely attributable to (i) the increase in sales orders volumes as a result of the expansion of product range offering; (ii) the appreciation of RMB against HK\$ of 9.1% in the six months ended 30 June 2021; and (iii) increase in sales of raw materials and dental equipment.

MANAGEMENT DISCUSSION AND ANALYSIS

AUSTRALIA

The Australian market includes both Australia and New Zealand. In Australia and New Zealand, individuals are primarily responsible for financing their own dental treatments. Our Australian region experienced unprecedented demand for its products and services for the first half of 2021 as revenues significantly exceeded pre-pandemic levels of 2019 (for the same period). The Group is focused on ensuring solid execution of its Australian business operationally and financially, driven by organic growth and acquisitions.

During the period under review, the Australian market recorded a revenue of approximately HK\$116,271,000, representing an increase of approximately HK\$42,314,000 as compared with the six months ended 30 June 2020. Together with the service revenue generated from rendering educational events and seminars and sales of dental equipment and other products of approximately HK\$11,238,000, this geographic market accounted for approximately 8.6% of the Group's total revenue as compared with approximately 8.3% in the six months ended 30 June 2020. The increase of revenue from the Australian market was largely attributable to the increase in sales order volume and the appreciation of AUD against HK\$ by 17.5% for the six months ended 30 June 2021 compared with six months ended 30 June 2020.

OTHERS

Other markets primarily include Indian Ocean countries, Japan, Taiwan and Singapore. During the period under review, these markets recorded a revenue of approximately HK\$17,090,000, representing an increase of approximately HK\$9,584,000 as compared with the six months ended 30 June 2020. Together with the revenue generated from sales of equipment of approximately HK\$931,000, this geographic market accounted for approximately 1.2% of the Group's total revenue as compared with approximately 0.8% in the six months ended 30 June 2020.

FUTURE PROSPECTS AND STRATEGIES

Notwithstanding any short term challenges the global economy may face such as the emergence of new variants of COVID-19, the Board is confident that the medium and long-term global demand for dental prosthetics is expected to continue due to key irreversible demographic factors and trends. While it may be unpredictable as to how the new variants of COVID-19 may affect our clients' businesses in the short term, it is evident that the lasting effects of the pandemic has disproportionately affected our smaller or mid-scaled competitors and has accelerated the adoption of intra-oral scanners by our customers in certain markets, which in turn, has the direct effect of accelerating the process of consolidation within our industry and ultimately benefiting the Group, as the global leader in the industry.

The unique global distribution network of the Group brings additional opportunities to the Group and the Board is of the view that through further acquisitions, continuing organic growth, additional distribution and joint venture arrangements with upstream suppliers, venturing into new markets and the introduction of new products (such as orthodontic devices), the Group will go from strength-to-strength in consolidating its status as the leading global dental prosthetic device provider.

The Group has operated over 35 years and has withstood various shocks within the global economy and natural disasters in the past decades and evidently the Group has come out stronger after the occurrence of each event. With the Board's extensive experience and determination to meet any short-term challenges, the Group is in an ideal position to take advantage of, and will remain opportunistic in, any business opportunities whilst remaining cautious and prudent in safeguarding shareholders' interests.

The Board is highly appreciative of the enormous efforts of our people, customers and suppliers during this unique time, as they work relentlessly to fulfil targets and maintaining daily operations.

MANAGEMENT DISCUSSION AND ANALYSIS

FINANCIAL REVIEW

REVENUE

During the period under review, the revenue of the Group amounted to approximately HK\$1,481,225,000 representing an increase of approximately 65.1% as compared with approximately HK\$897,223,000 in the six months ended 30 June 2020. The increase was largely attributable to (i) increase in sales orders volume; (ii) appreciation of foreign currencies against HK\$ when compared with same period in 2020; and (iii) increase in sales of dental equipment and clear aligner products.

GROSS PROFIT AND GROSS PROFIT MARGIN

The gross profit for the six months ended 30 June 2021 was approximately HK\$780,240,000, which was approximately 88.5% higher than that of the six months ended 30 June 2020. The increase of the gross profit margin of approximately 6.6% compared with the corresponding period in 2020 was mainly attributable to the increase in productivity of the production teams.

The gross profit margins of Fixed Prosthetic Devices business segment, Removable Prosthetic Devices business segment and Others business segment were approximately 54.0%, 53.1% and 46.9% respectively. The following table sets forth the breakdown of our gross profit and gross profit margin by product category.

Product category	Six months ended 30 June			
	2021		2020	
	Gross profit HK\$'000	Gross profit margin (%)	Gross profit HK\$'000	Gross profit margin (%)
Fixed prosthetic devices	530,055	54.0	299,362	47.8
Removable prosthetic devices	137,757	53.1	75,983	46.7
Others	112,428	46.9	38,678	35.7
Total	780,240	52.7	414,023	46.1

SELLING AND DISTRIBUTION EXPENSES

During the period under review, the selling and distribution expenses increased by approximately 60.9% from approximately HK\$99,468,000 for the six months ended 30 June 2020 to approximately HK\$160,002,000 for the six months ended 30 June 2021, accounting for approximately 10.8% of the Group's revenue, as compared with approximately 11.1% for the corresponding period in 2020. The increase in the selling and distribution expenses was in line with the increase in the Group's sales.

ADMINISTRATIVE EXPENSES

During the period under review, the administrative expenses increased by approximately 15.2% from approximately HK\$275,973,000 for the six months ended 30 June 2020 to approximately HK\$318,024,000 for the six months ended 30 June 2021, accounting for approximately 21.5% of the Group's revenue, as compared with approximately 30.8% for the corresponding period in 2020. The increase in the administrative expenses was primarily attributable to i) increase in labour costs to deal with the significant increase in sales and ii) the decrease in governments subsidies on labour costs under COVID-19 related employment support schemes. The decrease in the administrative expenses as a percentage of revenue was mainly due to the strengthened costs control measures and enhancement in the economies of scale as a result of the significant increase in sales.

MANAGEMENT DISCUSSION AND ANALYSIS

IMPAIRMENT OF GOODWILL

The Group recorded an one-off non-cash impairment loss of goodwill for North America's cash generating unit of approximately HK\$150,132,000 as a result of the on-going spreading of the COVID-19 in the North America region for the six months ended 30 June 2020. For details, please refer to Note 11 in this Interim Report. During the six months ended 30 June 2021, due to strong recovery of the dental industry, no indication of impairment is therefore noted, hence, no impairment loss of goodwill is therefore required to be made.

OTHER OPERATING EXPENSES

During the period under review, the other operating expenses decreased by approximately 41.7% from approximately HK\$5,099,000 for the six months ended 30 June 2020 to approximately HK\$2,974,000 for the six months ended 30 June 2021, accounting for approximately 0.2% of the Group's revenue, as compared with approximately 0.6% for the corresponding period in 2020. Other operating expenses mainly represented exchange losses, net, incurred of approximately HK\$2,924,000 (six months ended 30 June 2020: HK\$4,877,000).

FINANCE COSTS

During the period under review, the finance costs decreased by approximately 41.5% from approximately HK\$19,814,000 for the six months ended 30 June 2020 to approximately HK\$11,584,000 for the six months ended 30 June 2021, accounting for approximately 0.8% of the Group's revenue, as compared with approximately 2.2% for the corresponding period in 2020. The decrease was mainly due to decrease in the effective interest rate when compared with six months ended 30 June 2020.

INCOME TAX EXPENSE

During the period under review, the income tax expense increased by approximately 548.8% from approximately HK\$8,401,000 for the six months ended 30 June 2020 to approximately HK\$54,506,000 for the six months ended 30 June 2021.

PROFIT/(LOSS) FOR THE PERIOD

The turnaround from loss of approximately HK\$139,502,000 for the six months ended 30 June 2020 to profit of approximately HK\$240,005,000 for the six months ended 30 June 2021 was due to operating profit generated by the Group as a result of the strong sales performance; and no one-off non-cash impairment loss of goodwill for North America region recognised in the six months ended 30 June 2021 (six months ended 30 June 2020: HK\$150,132,000).

PROFIT/(LOSS) ATTRIBUTABLE TO OWNERS OF THE COMPANY

Profit attributable to owners of the Company amounted to approximately HK\$240,037,000, representing an increase of approximately HK\$379,391,000, or approximately 272.2%, as compared with loss attributable to owners of the Company approximately HK\$139,354,000 for the corresponding period in 2020.

NON-IFRS MEASURES

To supplement our consolidated financial statements, which are presented in accordance with the International Financial Reporting Standards (the "IFRS"), the Company also assesses the operating performance based on a measure of adjusted earnings before interest, tax, depreciation and amortisation (the "EBITDA") as additional financial measures. By means of these financial measures, the management of the Group is able to evaluate their financial performance regardless of the items they do not consider indicative of the operating performance of their business.

MANAGEMENT DISCUSSION AND ANALYSIS

EBITDA, ADJUSTED EBITDA AND PROFIT FROM CORE OPERATIONS

During the period under review, the Group incurred some one-off expenses, which are not indicative of the operating performance of the business of the period. Therefore, the Group arrived at an adjusted EBITDA (the "Adjusted EBITDA") and profit from core operations by eliminating the effects of certain non-cash or non-recurring items, including one-off transaction cost in connection with restructuring and reorganisation.

The table below indicates the profit/(loss) for the six months ended 30 June 2021 and 2020, reconciling the Adjusted EBITDA for the periods presented to the most comparable financial measures calculated in accordance with the IFRS:

	Six months ended 30 June	
	2021 HK\$'000	2020 HK\$'000
EBITDA and Adjusted EBITDA		
Net profit/(loss)	240,005	(139,502)
Tax	54,506	8,401
Finance costs	11,584	19,814
Depreciation of right-of-use assets	23,098	24,641
Depreciation of property, plant and equipment	31,403	29,877
Amortisation of intangible assets	14,865	14,963
Impairment of goodwill	—	150,132
Less:		
Bank interest income	(266)	(835)
EBITDA	375,195	107,491
Add:		
One-off cost in connection with restructuring and reorganisation	—	3,888
Adjusted EBITDA	375,195	111,379
Adjusted EBITDA Margin	25.3%	12.4%

MANAGEMENT DISCUSSION AND ANALYSIS

The table below indicates the profit/(loss) for the six months ended 30 June 2021 and 2020, reconciling the profit from core operations for the periods presented to the most comparable financial measures calculated in accordance with the IFRS:

	Six months ended 30 June	
	2021 HK\$'000	2020 HK\$'000
Profit from core operations		
Net profit/(loss)	240,005	(139,502)
Add:		
Impairment of goodwill	—	150,132
One-off cost in connection with restructuring and reorganisation	—	3,888
Profit from core operations	240,005	14,518
Profit from core operations Margin	16.2%	1.6%

LIQUIDITY AND FINANCIAL RESOURCES

CASH FLOWS

The table below summarises the Group's cash flows for the six months ended 30 June 2021 and 2020:

	Six months ended 30 June	
	2021 HK\$'000	2020 HK\$'000
Net cash flows from operating activities	246,840	77,313
Net cash flows used in investing activities	(44,561)	(23,647)
Net cash flows used in financing activities	(253,258)	(53,076)

The Group derives its working capital mainly from cash on hand, net cash generated from operating activities and financing activities. The Board expects that the Group will rely on the internally generated funds and the available bank facilities in the absence of unforeseen circumstances. There were no material changes in the funding and financial policies of the Group.

The Group's balance of cash and cash equivalents was approximately HK\$648,350,000 as of 30 June 2021 (31 December 2020: HK\$697,827,000), which was mainly denominated in HK\$, RMB, US\$, EUR and AUD.

OPERATING ACTIVITIES

Net cash flows from operating activities was approximately HK\$246,840,000 for the six months ended 30 June 2021 (six months ended 30 June 2020: HK\$77,313,000). The increase in net cash flows from operating activities was primarily driven by the increase in operating profit generated by the Group as a result of the strong sales performance.

MANAGEMENT DISCUSSION AND ANALYSIS

INVESTING ACTIVITIES

The Group recorded a net cash outflow used in investing activities of approximately HK\$44,561,000 for the six months ended 30 June 2021, of which approximately HK\$45,731,000 was used primarily for the upgrade of our computer-aided/manufacturing production equipment and renovation of factory premises, net off with proceeds from disposal of property, plant and equipment of approximately HK\$2,951,000.

FINANCING ACTIVITIES

The Group recorded a net cash outflow used in financing activities of approximately HK\$253,258,000 for the six months ended 30 June 2021. The outflow was mainly attributable to (i) repayment of bank borrowings of approximately HK\$145,000,000; (ii) payment for dividend of approximately HK\$66,986,000; (iii) repurchase of the Company's ordinary shares of approximately HK\$7,896,000; (iv) payment for lease liabilities of approximately HK\$26,186,000; and (v) payment for interest expenses of approximately HK\$7,190,000.

CAPITAL EXPENDITURE

During the period under review, the Group's capital expenditure amounted to approximately HK\$45,731,000 was used for improvement on our production equipment and renovation of factory premises. All of the capital expenditure was financed by internal resources and bank borrowings.

CAPITAL STRUCTURE

FUNDING AND TREASURY POLICIES

The management of the Group is dedicated to controlling the treasury activities of the Group by seeking opportunities to realise the Group's business strategies with an aim to obtain a higher return for the Shareholders at an appropriate risk exposure.

BANK LOANS

Bank loans of the Group as of 30 June 2021 amounted to approximately HK\$717,742,000 as compared to approximately HK\$860,743,000 as of 31 December 2020. Pledged bank deposits of the Group as of 30 June 2021 amounted to approximately HK\$4,748,000 as compared to approximately HK\$4,828,000 as of 31 December 2020. As of 30 June 2021, the bank loans of approximately HK\$681,688,000 and HK\$36,054,000 were denominated in HK\$ and RMB, respectively. As of 30 June 2021, all bank loans were at floating interest rates.

CASH AND CASH EQUIVALENTS

The amount in which cash and cash equivalents were held are set out in the paragraph headed "Liquidity and Financial Resources" on page 16 of this Interim Report.

GEARING RATIO

The Group monitors capital using a gearing ratio, which is net debt divided by the adjusted capital (equity attributable to owners of the Company) plus net debt. Net debt includes interest-bearing bank borrowings, trade payables, other payables and accruals, amount due to an associate, lease liabilities, less cash and cash equivalents and pledged deposits. As of 30 June 2021, the gearing ratio of the Group was approximately 19% (31 December 2020: 22%), reflecting that the Group's financial position was at a sound level.

MANAGEMENT DISCUSSION AND ANALYSIS

DEBT SECURITIES

As of 30 June 2021 and 31 December 2020, the Group did not have any debt securities.

CONTINGENT LIABILITIES

As of 30 June 2021 and 31 December 2020, the Group did not have any material contingent liabilities or guarantees.

CHARGE OF GROUP ASSETS

During the period under review, Modern Dental Holding Limited, a subsidiary of the Company, entered into certain bank loans facility agreements (the "**Facility Agreements**") for certain term loans and a revolving credit, secured by corporate guarantees of the Company and certain of its subsidiaries. Pursuant to the Facility Agreements, if the aggregate shareholding of Mr. Chan Kwun Fung, Mr. Chan Kwun Pan, Dr. Chan Ronald Yik Long, Ms. Chan Yik Yu, Mr. Ngai Chi Ho Alwin and Mr. Ngai Shing Kin, directly or indirectly, in the Company's share capital ceases to be at least 50%, the commitment under the Facility Agreements will be cancelled and all the outstanding amounts under the Facility Agreements will become immediately due and payable.

COMMITMENTS

The investment agreement was entered into between Modern Dental Laboratory Company Limited and Dongguan Songshan Lake High-tech Industrial Development Zone Management Committee. Pursuant to the agreement, Modern Dental Laboratory Company Limited would invest not less than RMB246,000,000 (equivalent to approximately HK\$295,645,000) for the acquisition of land, and construction and renovation of a factory in the Dongguan Songshan Lake High-tech Industrial Development Zone.

As of 30 June 2021, the Group has paid approximately RMB156,597,000 (equivalent to approximately HK\$188,199,000) for the construction and renovation of a factory and approximately RMB18,839,000 (equivalent to approximately HK\$22,641,000) for the acquisition of land, and the remaining commitment was approximately RMB70,564,000 (equivalent to approximately HK\$84,805,000).

Save as disclosed above, the Group had no significant capital commitments as of 30 June 2021.

DETAILS OF MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES AND FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

The Group had no material acquisitions and disposals of subsidiaries, associates and joint ventures during the six months ended 30 June 2021 and, save as disclosed in section headed "Important Events After the Period Under Review" there is no plan for material investments or capital assets as at the date of this Interim Report.

OFF-BALANCE SHEET TRANSACTIONS

As of 30 June 2021, the Group did not enter into any material off-balance sheet transactions.

MANAGEMENT DISCUSSION AND ANALYSIS

IMPORTANT EVENTS AFTER THE PERIOD UNDER REVIEW

- (i) Subsequent to the end of the period under review, 2,636,000 ordinary shares of approximately HK\$7,001,000 (before expenses) repurchased in six months ended 30 June 2021 were cancelled in July 2021.
- (ii) On 9 July 2021, MDPCH Pty Ltd, a wholly owned subsidiary of the Company, entered into a share purchase agreement with independent third parties, Panagiotis (Peter) Nouris and Alexander Petratos, to acquire a 100% equity interest of Swift Dental Laboratory ("**Swift**") at a cash consideration of AUD800,000 and a contingent consideration of AUD500,000. Swift is principally engaged in provision of dentures in Australian market. The acquisition was completed on 9 July 2021. The acquisition will provide the Group with an important foundation to build on its existing Australian-made denture work to further expand the Group's product offering and services to its existing clients.

Save as disclosed above, the Group has no important events after the period under review up to the date of this Interim Report.

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

The Group's business, financial condition and results of operations are subject to various business risks and uncertainties. The factors set out below are those that the Group believes could result in the Group's financial condition or results of operations differing materially from expected or historical results. There may be other risks in addition to those set out below which are not known to the Group or which may not be material now but could turn out to be material in the future.

GLOBAL ECONOMY AND CROSS COUNTRIES OPERATIONS

As a global business, the Group is exposed to the development of the global economy and continued changes in government policies, political, social, legal and regulatory requirements as well as the industries and geographical markets in which it operates. As a result, the Group's financial condition and results of operations may be influenced by the general state of the economy and operating environment of markets in which it operates. Any significant decrease in the level of economic growth in the global or regional or a specific economy could adversely affect the Group's financial condition or results of operations. On the other hand, the Group's global business covering different regions and countries also mitigates the Group's reliance on any single region or country.

For instance, the global COVID-19 pandemic has caused a global health emergency and significant disruptions to economies worldwide which could adversely impact the Group's operating results. The efficacy of the vaccines against new virus mutations, the new wave of infection particularly across developing countries with low vaccination rates, the effectiveness of policy support to facilitate the transition back to normalcy and the associated inflationary risks and supply constraints from subdued mobility caused by the pandemic, continue to pose risks and uncertainties ahead. The Group may continue to implement cost cutting measures (including salaries reduction, deferring marketing expenses, etc) to reduce the risks and uncertainties brought by the global COVID-19 pandemic.

MANAGEMENT DISCUSSION AND ANALYSIS

MERGERS AND ACQUISITIONS RISK

Goodwill and intangible assets arising from mergers and acquisitions accounted for significant portion in the Group's total assets. If there is any impairment on the goodwill and intangible assets, it will affect the profit of the Group.

The Group mitigates such risk by engagement of legal and financial advisers to carry out due diligence of material acquisitions. The Group has also engaged external valuer, Brilliant Appraisal Limited, to assess the impairment of material goodwill and intangible assets annually or indication of impairment noted and no material changes in key assumptions have been made in general on an annual basis. The key assumptions for 31 December 2020, such as the pre-tax discount rates (ranged between 13% and 20%); the budgeted sales growth rates (ranged between 0% and 10%); and budgeted EBITDA margins (ranged between 8% and 30%), are determined with reference to historical performance of the Group; market research of the prosthetic devices industry and the specific business plans of the Group. Please refer to Note 11 in this Interim Report for details.

CENTRALISATION OF PRODUCTION FACILITIES

The production of the Group relied heavily on its existing production facilities in Shenzhen, Mainland China and in Dongguan, Mainland China. If there are disruptions to the production sites in Shenzhen and Dongguan, the Group may suffer from interruptions to its business. During the six months ended 30 June 2021, the management has also started to set up a new production facility in Vietnam to further mitigate the risk. Apart from this, the Group has already had various smaller scale production sites in different parts of the world, such as the United States, Europe and Australia, etc, and will continue to explore opportunities around the world.

INTEREST RATE RISK

Our exposure to the interest rate risk relates primarily to our long-term debt obligations with floating interest rates. We manage our interest rate exposure with a focus on reducing our overall cost of debt and exposure to changes in interest rate. Our management continues to monitor the cash flows of our operation and the debt markets, where we would expect to refinance these borrowings with a lower cost of debt when desirable. For the six months ended 30 June 2021, the interest rate on floating-rate bank loans were approximately HIBOR+1.60% per annum for term loans and 1-year Loan Prime Rate for a revolving credit. The Group had not entered into any type of interest rate agreements or derivative transactions to hedge against the fluctuations in interest rates.

FOREIGN CURRENCY RISK

In light of the nature of our business, we are exposed to various foreign currencies, among which, RMB, EUR, AUD and US\$ are mostly used apart from HK\$. To minimise the impact of foreign currency rate volatility, we monitor foreign currency risk closely on an ongoing basis to ensure that the net exposure is at an acceptable level.

CREDIT RISK

The credit risk of our other financial assets, which comprise trade receivables, financial assets included in prepayments, deposits and other receivables, amount due from an associate and related parties, pledged deposits and cash and cash equivalents, arises from default of the counterparty, with a maximum exposure equal to the carrying amounts of these instruments.

Since we trade only with recognised and creditworthy third parties, there is no requirement for collateral. Concentrations of credit risk are managed by customer/counterparty, by geographical region and by industry sector. There are no significant concentrations of credit risk within our Group as the customer bases of our trade receivables are widely dispersed.

LIQUIDITY RISK

Our policy is to maintain sufficient cash and cash equivalents and to have available funding through bank borrowings.

OTHER INFORMATION

DIVIDENDS

In celebration of the Group's 35th anniversary and in special recognition of Chan Kwun Fung's (former Chairman) and Chan Kwun Pan's (former Vice-Chairman) extraordinary contribution to the Group for their decades of commitment, dedication and professionalism, the Board declared a special dividend of HK5.0 cents (six months ended 30 June 2020: Nil) per ordinary share, together with an interim dividend of HK7.5 cents (six months ended 30 June 2020: Nil) per ordinary share in six months ended 30 June 2021. The interim dividend and special dividend will be payable on Friday, 15 October 2021 to Shareholders whose names appear on the Register of Members of the Company on Wednesday, 29 September 2021.

CLOSURE OF REGISTER OF MEMBERS

The Register of Members of the Company will be closed from Monday, 27 September 2021 to Wednesday, 29 September 2021, both dates inclusive, during which period no transfer of shares of the Company will be registered. In order to qualify for entitlement to the interim dividend and special dividend for the six months ended 30 June 2021, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong for registration no later than 4:30 p.m. on Friday, 24 September 2021, for the purpose of effecting the share transfers.

EMOLUMENT POLICY AND DIRECTORS' REMUNERATION

In compliance with the Corporate Governance Code as set out in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**"), the Company has established the remuneration committee of the Company (the "**Remuneration Committee**") to formulate remuneration policies. The remuneration is determined and recommended based on each Director's and senior management personnel's qualifications, position and seniority. As for the independent non-executive Directors, their remuneration is determined by the Board upon recommendation from the Remuneration Committee. The Directors and the senior management personnel are eligible participants of the Share Option Scheme and the Pre-IPO RSU Scheme (both as defined below).

EMPLOYEE AND REMUNERATION POLICY

The Group had a total of 6,277 (31 December 2020: 5,838) full-time employees at our production facilities, service centers, points of sales and other sites as of 30 June 2021, mainly including 4,517 (31 December 2020: 4,219) production staff members, 660 (31 December 2020: 610) general management staff members and 358 (31 December 2020: 341) customer service staff members.

Total staff costs of the Group (including the Directors' and chief executive's remuneration) for the six months ended 30 June 2021 was approximately HK\$644,434,000 (six months ended 30 June 2020: approximately HK\$467,513,000). The Group's remuneration policies were in line with relevant legislation, market conditions and the performance of our employees.

In line with the performance of the Group and individual employees, a competitive remuneration package is offered to retain employees, including salaries, discretionary bonuses and contributions to benefit plans (including pensions). Employees of the Group are the eligible participants of the Share Option Scheme (as defined below). During the period under review, the relationship between the Group and our employees had been stable. We had not experienced any strikes or other labor disputes which materially affected our business activities.

OTHER INFORMATION

SHARE OPTION SCHEME

A share option scheme (the “**Share Option Scheme**”) was adopted pursuant to the written resolutions of the Shareholders passed on 25 November 2015 (the “**Share Option Scheme Adoption Date**”).

The purpose of the Share Option Scheme is to enable the Company to grant options to the eligible participants including any employee, director, supplier, customer, shareholder, research, development or other technological support personnel and advisor of the Group and invested entity of the Group and any other group or classes of participants who have contributed or may contribute by way of joint venture, business alliance or other business arrangement to the development and growth of the Group as the Directors determine, as an incentive or a reward for their contribution to the Group.

The maximum number of the ordinary shares of the Company (the “**Shares**”) which may be allotted and issued upon exercise of all outstanding options granted and yet to be exercised under the Share Option Scheme and any other share option schemes adopted by the Group must not exceed 30% of the issued share capital of the Company from time to time. No options may be granted under the Share Option Scheme or any other share option schemes adopted by the Group if the grant of such option exceeds the limit.

The total number of the Shares which may be allotted and issued upon exercise of all options to be granted under the Share Option Scheme and any other share option schemes adopted by the Group as from the Share Option Scheme Adoption Date (excluding, for this purpose, Shares issuable upon exercise of options which have been granted but which have lapsed in accordance with the Share Option Scheme or any other share option schemes of the Company) must not in aggregate exceed 10% of all Shares in issue upon the date of listing, i.e. 15 December 2015 (i.e. 100,000,000 Shares, representing 10.4% of the Shares in issue as at the date of this Interim Report). The limit of 10% may be refreshed at any time by approval of the Shareholders in a general meeting provided that the total number of the Shares which may be issued upon exercise of all options to be granted under the Share Option Scheme and any other option schemes of the Group must not exceed 10% of the Shares in issue as at the date of approval of the refreshed limit and for the purpose of calculating the limit, options (including those outstanding, cancelled, lapsed or exercised in accordance with the Share Option Scheme and any other share option schemes of our Group) previously granted under the Share Option Scheme and any other share option schemes of our Group will not be counted.

Unless approved by Shareholders in a general meeting, the maximum number of Shares underlying the options granted to each eligible participant (including both exercised and outstanding options) in any 12-month period shall not exceed 1% of the Shares in issue for the time being.

Where any grant of options to a substantial shareholder or an independent non-executive Director or any of their respective associates would result in the Shares allotted and issued and to be allotted and issued upon exercise of all options already granted and to be granted (including options exercised, cancelled and outstanding) to such person in the 12-month period up to and including the date of such grant:

- (i) representing in aggregate over 0.1% of the Shares in issue; and
- (ii) having an aggregate value, based on the closing price of the Shares at the offer date of each offer, in excess of HK\$5 million;

such further grant of options must be approved by Shareholders in general meeting.

OTHER INFORMATION

A consideration of HK\$1.0 is payable on acceptance of the grant of an option within such time as may be specified in the offer (which shall not be later than 21 days from the offer date).

Pursuant to the Share Option Scheme, the participants may subscribe for the Shares on the exercise of an option at the price determined by the Board provided that it shall be at least the highest of (a) the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the date on which an option is offered to a participant, which must be a business date (the "Offer Date"); (b) the average of the closing prices of the Shares as stated in the Stock Exchange's daily quotations sheets for the five business days immediately preceding the Offer Date; and (c) the nominal value of a Share.

An option may be exercised in accordance with the terms of the Share Option Scheme at any time during a period as the Board may determine, which may not expire later than 10 years from the Offer Date of the option subject to the provisions of early termination thereof. The Share Option Scheme shall be valid and effective for a period of 10 years commencing on the Share Option Scheme Adoption Date.

As at 30 June 2021, no options had been granted, agreed to be granted, exercised, cancelled or lapsed pursuant to the Share Option Scheme and therefore the total number of Shares available for grant under the Share Option Scheme was 100,000,000 Shares, representing 10.4% of the Shares in issue as of the date of this Interim Report.

PRE-IPO RESTRICTED SHARE UNIT SCHEME

A restricted share unit scheme (the "Pre-IPO RSU Scheme") was adopted pursuant to the written resolutions of the Shareholders passed on 19 June 2015 (the "Pre-IPO RSU Scheme Adoption Date"). The purpose of the Pre-IPO RSU Scheme is to give incentives thereto in order to retain key employees for the continual operation and development of the Group and to attract suitable personnel for further development of the Group. The Pre-IPO RSU Scheme shall be valid and effective for a period of 10 years commencing on the Pre-IPO RSU Scheme Adoption Date, under the administration of the Board and the trustee.

As at 30 June 2021, no outstanding restricted share units were granted or vested pursuant to the Pre-IPO RSU Scheme.

MANDATORY PROVIDENT FUND RETIREMENT BENEFIT SCHEME

The Group operates a defined contribution mandatory provident fund retirement benefit scheme (the "MPF Scheme") under the Mandatory Provident Fund Schemes Ordinance for all of its employees in Hong Kong. Under the MPF Scheme, the employees are required to contribute 5% of their monthly salaries or up to a maximum of HK\$1,500 and they can choose to make additional contributions. The employer's monthly contributions are calculated at 5% of the employee's monthly salaries or up to a maximum of HK\$1,500. The employees are entitled to 100% of the employer's mandatory contributions upon their retirement at the age of 65, death or total incapacity.

DIRECTORS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY OF ITS ASSOCIATED CORPORATIONS

As at 30 June 2021, the interests and short positions of the Directors in the Shares, underlying Shares and debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO"), as recorded in the register maintained by the Company pursuant to Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") were as follows:

OTHER INFORMATION

LONG POSITIONS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

Name of Director	Capacity	Number of Shares and underlying Shares interested	Total number of Shares and underlying Shares interested	Approximate percentage of shareholding
Mr. Chan Kwun Fung	Beneficial owner	466,000 ^(Note 1)	474,375,263	49.44%
	Other	3,450,000 ^(Note 1)		
	Interest of controlled corporation	470,459,263 ^(Note 1)		
Mr. Chan Kwun Pan	Beneficial owner	3,450,000 ^(Note 1)	474,375,263	49.44%
	Other	466,000 ^(Note 1)		
	Interest of controlled corporation	470,459,263 ^(Note 1)		
Mr. Ngai Shing Kin	Beneficial owner	4,191,345	98,040,998	10.22%
	Interest of controlled corporation	93,849,653 ^(Note 2)		
Mr. Ngai Chi Ho Alwin	Beneficial owner	277,934	63,122,304	6.58%
	Interest of controlled corporation	62,844,370 ^(Note 3)		

Notes:

- Mr. Chan Kwun Fung and Mr. Chan Kwun Pan signed a confirmation letter on 10 August 2015 confirming their acting-in-concert arrangement whereby they operate the Group collectively, through discussions, and reached consensus between themselves before making any commercial decisions for the Group on a unanimous basis. As such and by virtue of the SFO, (i) each of Mr. Chan Kwun Fung and Mr. Chan Kwun Pan is deemed to be interested in the 470,459,263 Shares owned by Trieria Holdings Limited, (ii) Mr. Chan Kwun Fung is deemed to be interested in the 3,450,000 Shares owned by Mr. Chan Kwun Pan, and (iii) Mr. Chan Kwun Pan is deemed to be interested in the 466,000 Shares owned by Mr. Chan Kwun Fung.
- These Shares were held by Prosperity Worldwide Investment Holdings Limited, which is wholly owned by Mr. Ngai Shing Kin.
- These Shares were held by NCHA Holdings Limited, which is wholly owned by Mr. Ngai Chi Ho Alwin.

Save as disclosed above, as at 30 June 2021, none of the Directors and chief executives of the Company has any interest or short position in the Shares, underlying Shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to Model Code.

OTHER INFORMATION

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in the section headed "Directors' Interests and Short Positions in Shares and Underlying Shares and Debentures of the Company or any of its Associated Corporations" in this Interim Report, at no time during the six months ended 30 June 2021 was the Company or any of its subsidiaries a party to any arrangements to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of the Company or any other body corporate; and none of the Directors, or any of their spouse or children under the age of 18, had any right to subscribe for equity or debt securities of the Company or any other body corporate, or had exercised any such right.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at 30 June 2021, the persons other than the Directors, whose interests have been disclosed in the above section headed "Directors' Interests and Short Positions in Shares and Underlying Shares and Debentures of the Company or any of its Associated Corporations", had an interest or short position in the Shares and underlying Shares as recorded in the register required to be kept by the Company, pursuant to Section 336 of the SFO, were as follows:

LONG POSITIONS IN SHARES OF THE COMPANY

Name of Shareholder	Capacity	Number of Shares interested	Approximate percentage of shareholding
Triera Holdings Limited ^(Note 1)	Beneficial owner	470,459,263	49.03%
Prosperity Worldwide Investment Holdings Limited ^(Note 2)	Beneficial owner	93,849,653	9.78%
NCHA Holdings Limited ^(Note 3)	Beneficial owner	62,844,370	6.55%

Notes:

1. Triera Holdings Limited is a company incorporated in the British Virgin Islands and is owned as to 50%, 20%, 16% and 14% by Mr. Chan Kwun Fung, Mr. Chan Kwun Pan, Dr. Chan Ronald Yik Long and Ms. Chan Yik Yu, respectively.
2. Prosperity Worldwide Investment Holdings Limited is a company incorporated in the British Virgin Islands and is wholly owned by Mr. Ngai Shing Kin.
3. NCHA Holdings Limited is a company incorporated in the British Virgin Islands and is wholly owned by Mr. Ngai Chi Ho Alwin.

Save as disclosed herein, as at 30 June 2021, no person, other than the Directors whose interests are set out in the section headed "Directors' Interests and Short Positions in Shares and Underlying Shares and Debentures of the Company or any of its Associated Corporations" above, had any interests or short positions in the Shares or underlying Shares as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the six months ended 30 June 2021, the Company repurchased 3,286,000 of its Shares on the Stock Exchange at an aggregate consideration of approximately HK\$7,896,000 (before expenses), details of the repurchase are summarised as follows:

Month	Number of Shares repurchased	Price per Share		Aggregate consideration paid (before expenses) HK\$'000
		Highest HK\$	Lowest HK\$	
January 2021	650,000	1.43	1.34	895
March 2021	241,000	1.83	1.76	432
April 2021	2,166,000	3.91	2.34	5,662
May 2021	229,000	3.99	3.90	907
	3,286,000			7,896

Out of 3,286,000 repurchased Shares, 650,000 Shares of approximately HK\$895,000 (before expenses) were cancelled during the six months ended 30 June 2021, while the remaining 2,636,000 Shares of approximately HK\$7,001,000 (before expenses) were recognised as treasury shares as at 30 June 2021 and subsequently cancelled in July 2021.

The repurchase of the Company's Shares were effected by the directors, pursuant to the mandate from Shareholders received at the annual general meetings on 28 May 2020 and 27 May 2021, with a view to be benefiting Shareholders as a whole by enhancing the net assets value per share and earnings per share of the Group.

Save as disclosed above, during the six months ended 30 June 2021, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities.

CHANGES OF DIRECTORS' INFORMATION

During the six months ended 30 June 2021 and up to the date of this Interim Report, changes in information of Directors are as follows:

1. Mr. Chan Kwun Fung retired as the chairman of the Board and Dr. Chan Ronald Yik Long succeed Mr. Chan Kwun Fung as the chairman of the Board effective from 31 March 2021.
2. Mr. Chan Kwun Pan retired as the vice chairman of the Board and Mr. Ngai Chi Ho Alwin succeed Mr. Chan Kwun Pan as the vice chairman of the Board effective from 31 March 2021.
3. Dr. Wong Ho Ching retired as an independent non-executive Director and ceased to be the chairman of the Remuneration Committee and a member of the audit committee of the Company (the "Audit Committee") effective from 27 May 2021.
4. Dr. Yau Ka Po was appointed as an independent non-executive Director and a member of each of the Remuneration Committee and the Audit Committee effective from 27 May 2021.

OTHER INFORMATION

5. Dr. Cheung Wai Man William was appointed as the chairman of the Remuneration Committee effective from 27 May 2021.
6. Dr. Cheung Wai Bun Charles J.P. has been resigned as an independent non-executive director of Yin He Holdings Limited (stock code: 8260), which is listed on the GEM of the Stock Exchange, on 23 August 2021.

Save as disclosed in this Interim Report, there are no changes to the Directors' information as required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

CORPORATE GOVERNANCE

During the six months ended 30 June 2021, the Company has complied with the applicable code provisions of the Corporate Governance Code contained in Appendix 14 to the Listing Rules.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS OF THE COMPANY

The Company has adopted the Securities Dealing Code containing the provisions set out in the Model Code as set out in Appendix 10 to the Listing Rules, and after having made specific enquiries with regard to securities transactions by the Directors, all Directors have confirmed their compliance with the required standards set out in the Model Code regarding Directors' securities transactions during the six months ended 30 June 2021.

REVIEW OF INTERIM RESULTS

The Audit Committee consists of Dr. Cheung Wai Bun Charles J.P., Dr. Chan Yue Kwong Michael and Dr. Yau Ka Po, who are independent non-executive Directors. The Group's interim results for the six months ended 30 June 2021, including the accounting principles and practices adopted by the Group, have been reviewed by the Audit Committee.

ENVIRONMENTAL POLICIES AND PERFORMANCE

The Group is committed to fulfilling social responsibility, promoting employee benefits and development, protecting the environment and giving back to community and achieving sustainable growth.

MODERN DENTAL AND THE COMMUNITY

As a global company, the Company is committed to being a company that cares for the community, through engaging in sponsorships, donations, voluntary dental consultation and social services. We aim to provide services to the public and make positive contribution to the society. We will continue to be actively involved in community activities and dedicate our efforts to the future generation with a view to taking up our social responsibility with proactive efforts.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2021

	Notes	Six months ended 30 June	
		2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
REVENUE	4	1,481,225	897,223
Cost of sales		(700,985)	(483,200)
Gross profit		780,240	414,023
Other income and gains	4	6,480	5,807
Selling and distribution expenses		(160,002)	(99,468)
Administrative expenses		(318,024)	(275,973)
Impairment of goodwill	11	—	(150,132)
Other operating expenses		(2,974)	(5,099)
Finance costs	6	(11,584)	(19,814)
Share of profits/(losses) of associates		375	(445)
PROFIT/(LOSS) BEFORE TAX	5	294,511	(131,101)
Income tax expense	7	(54,506)	(8,401)
PROFIT/(LOSS) FOR THE PERIOD		240,005	(139,502)
ATTRIBUTABLE TO:			
Owners of the Company		240,037	(139,354)
Non-controlling interests		(32)	(148)
		240,005	(139,502)
EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY			
Basic	8	HK25.06 cents	HK(14.48) cents
Diluted	8	HK25.06 cents	HK(14.48) cents

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2021

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
PROFIT/(LOSS) FOR THE PERIOD	240,005	(139,502)
OTHER COMPREHENSIVE LOSS		
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	(25,987)	(22,777)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	(25,987)	(22,777)
TOTAL COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD	214,018	(162,279)
ATTRIBUTABLE TO:		
Owners of the Company	214,050	(162,131)
Non-controlling interests	(32)	(148)
	214,018	(162,279)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2021

	Notes	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
NON-CURRENT ASSETS			
Property, plant and equipment	10	528,636	518,915
Right-of-use assets		171,003	162,867
Goodwill	11	1,217,200	1,240,088
Intangible assets	12	272,025	287,670
Investments in an associate		3,009	761
Deferred tax assets		51,993	49,294
Long term prepayments and deposits	14	22,645	14,756
Total non-current assets		2,266,511	2,274,351
CURRENT ASSETS			
Inventories		144,048	128,021
Trade receivables	13	553,091	473,105
Prepayments, deposits and other receivables	14	90,791	71,783
Due from an associate		—	4,159
Current tax assets		10,469	11,014
Pledged deposits	15	4,748	4,828
Cash and cash equivalents	15	648,350	697,827
Total current assets		1,451,497	1,390,737
CURRENT LIABILITIES			
Trade payables	16	83,238	67,670
Other payables and accruals	17	227,423	230,627
Due to an associate		1,489	—
Interest-bearing bank borrowings	18	198,612	187,680
Lease liabilities		53,206	41,395
Tax payable		111,547	73,881
Total current liabilities		675,515	601,253
NET CURRENT ASSETS		775,982	789,484
TOTAL ASSETS LESS CURRENT LIABILITIES		3,042,493	3,063,835

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2021

	Notes	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
TOTAL ASSETS LESS CURRENT LIABILITIES		3,042,493	3,063,835
NON-CURRENT LIABILITIES			
Interest-bearing bank borrowings	18	519,130	673,063
Lease liabilities		118,719	123,005
Deferred tax liabilities		8,991	11,250
Total non-current liabilities		646,840	807,318
NET ASSETS		2,395,653	2,256,517
EQUITY			
Equity attributable to owners of the Company			
Share capital	19	74,367	74,592
Treasury shares		(7,040)	(3,106)
Reserves		2,319,502	2,176,175
Non-controlling interests		2,386,829	2,247,661
		8,824	8,856
TOTAL EQUITY		2,395,653	2,256,517

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2021

	Attributable to owners of the Company									Total equity HK\$'000
	Share capital HK\$'000	Share premium HK\$'000	Treasury shares HK\$'000	Statutory reserve HK\$'000	Capital reserve HK\$'000	Exchange reserve HK\$'000	Retained profits HK\$'000	Total HK\$'000	Non-controlling interests HK\$'000	
	At 1 January 2021 (audited)	74,592	566,614	(3,106)	18,912	556,017	(86,136)	1,120,768	2,247,661	
Profit for the period	—	—	—	—	—	—	240,037	240,037	(32)	240,005
Other comprehensive loss for the period:										
Exchange differences on translation of foreign operations	—	—	—	—	—	(25,987)	—	(25,987)	—	(25,987)
Total comprehensive income for the period	—	—	—	—	—	(25,987)	240,037	214,050	(32)	214,018
Transfer from retained earnings	—	—	—	2,486	—	—	(2,486)	—	—	—
2020 final dividend	—	(66,986)	—	—	—	—	—	(66,986)	—	(66,986)
Shares repurchased	—	—	(7,896)	—	—	—	—	(7,896)	—	(7,896)
Shares cancelled	(225)	(3,737)	3,962	—	225	—	(225)	—	—	—
At 30 June 2021 (unaudited)	74,367	495,891 [#]	(7,040)	21,398 [#]	556,242 [#]	(112,123) [#]	1,358,094 [#]	2,386,829	8,824	2,395,653

[#] These reserve accounts comprise the consolidated reserves of approximately HK\$2,319,502,000 (unaudited) (30 June 2020: HK\$1,756,097,000 (unaudited)) in the interim condensed consolidated statements of financial position.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2021

	Attributable to owners of the Company									Total equity HK\$'000
	Share capital	Share premium	Treasury shares	Statutory reserve	Capital reserve	Exchange reserve	Retained profits	Total	Non-controlling interests	
	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	
At 1 January 2020 (audited)	76,078	614,924	(21,796)	17,068	554,531	(236,320)	1,016,335	2,020,820	1,587	2,022,407
Loss for the period	—	—	—	—	—	—	(139,354)	(139,354)	(148)	(139,502)
Other comprehensive loss for the period:										
Exchange differences on translation of foreign operations	—	—	—	—	—	(22,777)	—	(22,777)	—	(22,777)
Total comprehensive loss for the period	—	—	—	—	—	(22,777)	(139,354)	(162,131)	(148)	(162,279)
Transfer from retained earnings	—	—	—	1,053	—	—	(1,053)	—	—	—
2019 final dividend	—	(21,172)	—	—	—	—	—	(21,172)	—	(21,172)
Shares repurchased	—	—	(6,867)	—	—	—	—	(6,867)	—	(6,867)
Shares cancelled	(1,486)	(27,138)	28,624	—	1,486	—	(1,486)	—	—	—
At 30 June 2020 (unaudited)	74,592	566,614 [#]	(39)	18,121 [#]	556,017 [#]	(259,097) [#]	874,442 [#]	1,830,650	1,439	1,832,089

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2021

	Notes	Six months ended 30 June	
		2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit/(loss) before tax		294,511	(131,101)
Adjustments for:			
Finance costs	6	11,584	19,814
Bank interest income	4,5	(266)	(835)
Gains on disposal of items of property, plant and equipment, net	4,5	(98)	(203)
Write-off of property, plant and equipment	5	19	72
Depreciation and amortisation	5	69,366	69,481
Impairment of goodwill	5	—	150,132
Share of (profits)/losses of associates		(375)	445
		374,741	107,805
(Increase)/decrease in inventories		(16,005)	1,602
(Increase)/decrease in trade receivables		(81,750)	28,018
Increase in prepayments, deposits and other receivables		(27,331)	(2,485)
Decrease/(increase) in amounts due from related parties		240	(49)
Decrease in balance with an associate		5,648	182
Increase/(decrease) in trade payables		15,997	(16,218)
Decrease in other payables and accruals		(3,645)	(44,067)
Decrease in amount due to a related party		(5)	(87)
		267,890	74,701
Cash generated from operations		267,890	74,701
Interest received		266	835
Income tax (paid)/refund		(21,316)	1,777
		246,840	77,313
Net cash flows from operating activities		246,840	77,313

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2021

	Notes	Six months ended 30 June	
		2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchases of items of property, plant and equipment and intangible assets		(45,731)	(26,338)
Proceeds from disposal of items of property, plant and equipment		2,951	2,569
Capital contribution for investments in an associate		(1,861)	—
Decrease in pledged deposits	15	80	122
Net cash flows used in investing activities		(44,561)	(23,647)
CASH FLOWS FROM FINANCING ACTIVITIES			
New bank borrowings		—	198,751
Repayment of bank borrowings		(145,000)	(179,875)
Dividend paid		(66,986)	(21,172)
Interest paid		(7,190)	(14,628)
Repurchases of shares		(7,896)	(6,867)
Payment for the principal portion of lease liabilities		(23,381)	(26,175)
Payment for the interest portion of lease liabilities		(2,805)	(3,110)
Net cash flows used in financing activities		(253,258)	(53,076)
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS			
Effect of foreign exchange rate changes, net		1,502	(851)
Cash and cash equivalents at beginning of period		697,827	393,905
CASH AND CASH EQUIVALENTS AT END OF PERIOD			
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
Cash and bank balances	15	648,350	393,427
Non-pledged time deposits with original maturity of less than three months when acquired	15	—	217
Cash and cash equivalents as stated in the interim condensed consolidated statement of financial position	15	648,350	393,644

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

1. CORPORATE AND GROUP INFORMATION

Modern Dental Group Limited (the “**Company**”) was incorporated as an exempted company with limited liability in the Cayman Islands on 5 July 2012 under the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised). The Company’s registered office address is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands. The Company and its subsidiaries (collectively referred to as the “**Group**”) are principally engaged in the production and distribution of dental prosthetic devices.

2.1 BASIS OF PREPARATION

The interim condensed consolidated financial statements for the six months ended 30 June 2021 have been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on the Main Board of The Stock Exchange of Hong Kong Limited (“**Listing Rules**”), including compliance with International Accounting Standard (“**IAS**”) 34 *Interim Financial Reporting*.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of Modern Dental Group Limited and its subsidiaries since the 2020 annual financial statements. The interim condensed consolidated financial statements and notes thereon do not include all of the information required for a full set of annual consolidated financial statements prepared in accordance with International Financial Reporting Standards (“**IFRSs**”), and should be read in conjunction with the Group’s annual consolidated financial statements as at 31 December 2020.

The interim condensed consolidated financial statements are unaudited, but have been reviewed by the Audit Committee of the Company.

2.2 CHANGES IN ACCOUNTING POLICIES

The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2020, except for the adoption of following revised standards for the first time for the current period’s financial statements.

Amendments to IFRS 9, IAS 39, IFRS 7,
IFRS 4 and IFRS 16

Interest Rate Benchmark Reform – Phase 2

Amendments to IFRS 16

Covid-19-Related Rent Concessions beyond 30 June 2021
(early adopted)

The adoption of these revised IASs and IFRSs did not have any significant effect on the financial position or performance of the Group.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

2.3 SIGNIFICANT ACCOUNTING JUDGEMENTS AND ESTIMATES

The preparation of the interim condensed consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and their accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that could require a material adjustment to the carrying amounts of the assets or liabilities affected in the future.

ESTIMATION UNCERTAINTY

IMPAIRMENT OF GOODWILL

The Group determines whether goodwill is impaired at least on an annual basis. This requires an estimation of the value in use of the cash-generating units to which the goodwill is allocated. Estimating the value in use requires the Group to make an estimate of the expected future cash flows from the cash-generating units and also to choose a suitable discount rate in order to calculate the present value of cash flows. The carrying amount of goodwill at 30 June 2021 was HK\$1,217,200,000 (31 December 2020: HK\$1,240,088,000). Further details are given in note 11 to the interim condensed consolidated financial statements.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group is organised into business units based on their products and services and has three reportable operating segments as follows:

- (a) The fixed prosthetic devices segment is a supplier of restorative dental procedures, such as crowns, bridges and implants.
- (b) The removable prosthetic devices segment produces full dentures and partial dentures. Dentures can be further classified as dentures with metal frameworks and dentures without metal frameworks.
- (c) The "others" segment comprises, principally, orthodontic devices (including clear aligner), sport guards and anti-snoring devices, raw materials, dental equipment, the service of educational events and seminars rendered.

Management monitors the revenue and cost of the Group's operating segments separately for the purpose of making decisions about resources allocation and performance assessment. Segment performance is evaluated based on reportable segment gross profit.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

3. OPERATING SEGMENT INFORMATION (CONTINUED)

Intersegment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

	Six months ended 30 June					
	2021 (unaudited)			2020 (unaudited)		
	Revenue HK\$'000	Cost of sales HK\$'000	Gross profit HK\$'000	Revenue HK\$'000	Cost of sales HK\$'000	Gross profit HK\$'000
Fixed prosthetic devices	982,020	451,965	530,055	626,175	326,813	299,362
Removable prosthetic devices	259,626	121,869	137,757	162,602	86,619	75,983
Others	239,579	127,151	112,428	108,446	69,768	38,678
Total	1,481,225	700,985	780,240	897,223	483,200	414,023

GEOGRAPHICAL INFORMATION

(A) REVENUE FROM EXTERNAL CUSTOMERS

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
	Europe	642,190
North America	361,628	240,286
Greater China	331,877	190,176
Australia	127,509	74,469
Others	18,021	7,506
Total	1,481,225	897,223

The revenue information above is based on the locations of the customers.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

3. OPERATING SEGMENT INFORMATION (CONTINUED)

GEOGRAPHICAL INFORMATION (CONTINUED)

(B) NON-CURRENT ASSETS

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Europe	741,510	773,781
North America	540,967	540,642
Australia	447,980	458,110
Greater China	407,411	377,279
Others	76,650	75,245
	2,214,518	2,225,057

The non-current assets information above is based on the locations of the assets and excludes deferred tax assets.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

4. REVENUE, OTHER INCOME AND GAINS

Revenue represents the net invoiced value of goods sold, after allowances for returns and trade discounts. An analysis of revenue, other income and gains is as follows:

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
<u>Revenue</u>		
Sale of goods transferred at a point in time	1,481,225	897,223
<u>Other income</u>		
Bank interest income	266	835
Government subsidies*	2,261	1,282
Others	3,855	3,487
	6,382	5,604
<u>Gains</u>		
Gains on disposal of items of property, plant and equipment, net	98	203
	98	203
Other income and gains	6,480	5,807

* Government subsidies contain the stabilisation subsidy and special fund of self-independent innovation industry from the government. There are no unfulfilled conditions or contingencies relating to these subsidies.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

5. PROFIT/(LOSS) BEFORE TAX

The Group's profit/(loss) before tax is arrived at after charging/(crediting):

	Notes	Six months ended 30 June	
		2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
Cost of inventories sold [#]		700,985	483,200
Depreciation of right-of-use assets		23,098	24,641
Depreciation of property, plant and equipment	10	31,403	29,877
Amortisation of intangible assets	12	14,865	14,963
Lease payments not included in the measurement of lease liabilities		5,687	2,451
Research and development costs ^{##}		3,537	3,187
Auditors' remuneration		5,439	4,836
Employee benefit expense (including directors' and chief executive's remuneration):			
Wages and salaries*		570,017	416,097
Pension scheme contributions		74,417	51,416
		644,434	467,513
Bank interest income	4	(266)	(835)
Gains on disposal of items of property, plant and equipment, net ^{**}	4	(98)	(203)
Write-off of property, plant and equipment ^{**}	10	19	72
Impairment of goodwill	11	—	150,132
Allowance for impairment of trade receivables, net	13	—	5,460
Reversal of allowance for impairment of trade receivables, net	13	(958)	—
Foreign exchange loss, net ^{**}		2,924	4,877

[#] Cost of inventories sold includes HK\$415,582,000 (unaudited) (six months ended 30 June 2020: HK\$296,479,000 (unaudited)) relating to employee benefit expense, lease payments not included in the measurement of lease liabilities and depreciation, which are also included in the respective total amounts disclosed above for each of these types of expenses.

^{##} Research and development costs includes HK\$2,731,000 (unaudited) (six months ended 30 June 2020: HK\$2,659,000 (unaudited)) relating to employee benefit expense, lease payments not included in the measurement of lease liabilities and depreciation, which are also included in the respective total amounts disclosed above for each of these types of expenses.

* The amount has been net-off with government subsidies of Nil (unaudited) (six months ended 30 June 2020: HK\$13,555,000 (unaudited)) under COVID-19 related employment support schemes. There were no unfulfilled conditions or contingencies relating to these subsidies.

** Gains on disposal of items of property, plant and equipment, net are included in "other income and gains" in the interim condensed consolidated statements of profit or loss. Write-off of property, plant and equipment and foreign exchange loss, net are included in "other operating expenses" in the interim condensed consolidated statements of profit or loss.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

6. FINANCE COSTS

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
Interest on bank loans, overdrafts and other loans	7,190	14,628
Finance charges on bank loans	1,589	2,076
Interest on lease liabilities	2,805	3,110
	11,584	19,814

7. INCOME TAX EXPENSE

The Group calculates the income tax expense for the period using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the interim condensed consolidated statement of profit or loss are:

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
Current – Hong Kong	34,646	5,760
Current – Elsewhere	24,881	4,709
Deferred	(5,021)	(2,068)
	54,506	8,401

8. EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY

The calculation of the basic earnings/(loss) per share amount is based on the profit/(loss) for the six months ended 30 June 2021 and 2020 attributable to ordinary equity holders of the Company, and the weighted average number of ordinary shares in issue during the period.

The calculation of the diluted earnings/(loss) per share amount is based on the profit/(loss) for the six months ended 30 June 2021 and 2020 attributable to ordinary equity holders of the Company. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the period, as used in the basic earnings/(loss) per share calculation.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

8. EARNINGS/(LOSS) PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE COMPANY (CONTINUED)

The Group had no potentially dilutive ordinary shares in issue during the six months ended 30 June 2021 and 2020. The calculations of basic and diluted earnings/(loss) per share are based on:

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
<u>Earnings/(loss)</u>		
Profit/(loss) attributable to ordinary equity holders of the Company, used in the basic and diluted earnings/(loss) per share calculation	240,037	(139,354)

	Number of shares Six months ended 30 June	
	2021 (Unaudited)	2020 (Unaudited)
<u>Shares</u>		
Weighted average number of ordinary shares in issue during the period used in the basic and diluted earnings/(loss) per share calculation	958,017,187	962,431,994

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

9. DIVIDENDS

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
Interim dividend	71,968	—
Special dividend	47,979	—

The Board declared an interim dividend of HK7.5 cents and a special dividend of HK5.0 cents per share for the six months ended 30 June 2021 (six months ended 30 June 2020: Nil). The interim dividend and special dividend are not recognised as a liability as at 30 June 2021 because they have been declared after the end of the reporting period

In 2021, the calculation of the interim dividend and special dividend are based on 959,577,000 ordinary shares in issue.

10. PROPERTY, PLANT AND EQUIPMENT

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Carrying amount at 1 January	518,915	498,613
Additions	42,447	66,243
Acquisition of a subsidiary	—	6,442
Disposals	(2,853)	(17,864)
Write-off	(19)	(319)
Depreciation provided during the period/year	(31,403)	(58,641)
Exchange realignment	1,549	24,441
Carrying amount at 30 June/31 December	528,636	518,915

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

11. GOODWILL

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Carrying amount at 1 January	1,240,088	1,310,846
Impairment during the period/year	—	(150,132)
Exchange realignment	(22,888)	79,374
Carrying amount at 30 June/31 December	1,217,200	1,240,088

IMPAIRMENT TESTING OF GOODWILL

In accordance with IAS 36, the recoverable amounts of the Group's cash generating units ("CGUs") including those which contain goodwill were determined using the higher of fair value less cost to sell and value in use, which is determined by discounting the estimated future cash flows generated from the continuing use of the unit. Management performed impairment testing of goodwill annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired.

For the six months ended 30 June 2021, the Group's revenue demonstrates a strong growth, no indication of impairment is therefore noted, no impairment testing of goodwill is therefore performed.

For the year ended 31 December 2020, as a result of material impact on the global economy and market conditions caused by the COVID-19 pandemic, the Group determined there were indicators of potential impairment on certain CGUs at 30 June 2020. Based on the valuation performed by an external valuer, Brilliant Appraisal Limited, engaged by the Company, it was determined that the carrying value of our CGU in North America, being MicroDental and Modern US, of HK\$658,147,000 was greater than its recoverable amount of HK\$508,015,000, resulting in impairment on goodwill amounted to HK\$150,132,000 due to the on-going spreading of the COVID-19 in the North America region during that period. The recoverable amounts of CGUs were reassessed at 31 December 2020 and no further impairment on goodwill was considered necessary.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

12. INTANGIBLE ASSETS

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Carrying amount at 1 January	287,670	295,145
Additions	3,284	5,935
Amortisation provided during the period/year	(14,865)	(29,452)
Exchange realignment	(4,064)	16,042
Carrying amount at 30 June/31 December	272,025	287,670

13. TRADE RECEIVABLES

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Trade receivables	584,106	506,090
Impairment	(31,015)	(32,985)
	553,091	473,105

The Group normally allows credit terms of 30 to 90 days to established customers, and extends credit terms up to 180 days for major customers. The Group seeks to maintain strict control over its outstanding receivables. Overdue balances are reviewed regularly by senior management. In view of the aforementioned and the fact that the Group's trade receivables relate to a large number of diversified customers, there is no significant concentration of credit risk. The Group does not hold any material collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

13. TRADE RECEIVABLES (CONTINUED)

An ageing analysis of the trade receivables as at 30 June 2021 and 31 December 2020, based on the invoice date and net of loss allowance, is as follows:

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Within 1 month	347,701	282,483
1 to 2 months	62,581	63,603
2 to 3 months	40,317	33,811
3 months to 1 year	85,877	70,541
Over 1 year	16,615	22,667
	553,091	473,105

The movements in provision for impairment of trade receivables are as follows:

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
At 1 January	32,985	26,887
Impairment loss, net (note 5)	(958)	5,053
Amount written off as uncollectible	(947)	(294)
Exchange realignment	(65)	1,339
At 30 June/31 December	31,015	32,985

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

14. PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Current		
Prepayments	45,304	22,656
Deposits and other receivables	45,487	48,887
Due from related parties (note 23(3))	—	240
	90,791	71,783
Non-current		
Prepayments	4,560	791
Deposits	18,085	13,965
	22,645	14,756

15. CASH AND CASH EQUIVALENTS AND PLEDGED DEPOSITS

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Cash and bank balances	648,350	697,751
Time deposits	4,748	4,904
	653,098	702,655
Less: Pledged deposits	(4,748)	(4,828)
Cash and cash equivalents	648,350	697,827

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

16. TRADE PAYABLES

An ageing analysis of the trade payables as at 30 June 2021 and 31 December 2020, based on the invoice date, is as follows:

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Within 1 month	48,821	48,795
1 to 2 months	21,982	10,585
2 to 3 months	8,613	4,623
Over 3 months	3,822	3,667
	83,238	67,670

The trade payables are unsecured, non-interest-bearing and are normally repayable within one to three months or on demand. The carrying amounts of trade payables approximate to their fair values due to their relatively short maturity terms.

17. OTHER PAYABLES AND ACCRUALS

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Current		
Contract liabilities	10,861	8,744
Deferred revenue	1,285	2,937
Accruals	161,865	164,544
Other payables	48,607	49,592
Due to a related party (note 23(3))	5	10
Due to a non-controlling shareholder	4,800	4,800
	227,423	230,627

The balances are unsecured and non-interest-bearing. The carrying amounts of other payables and accruals approximate to their fair values.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

18. INTEREST-BEARING BANK BORROWINGS

	30 June 2021 (Unaudited)			31 December 2020 (Audited)		
	Effective/ contractual interest rate (%)	Maturity	HK\$'000	Effective/ contractual interest rate (%)	Maturity	HK\$'000
Current						
Bank loans – secured	1-year Loan Prime Rate	On demand	36,054	1-year Loan Prime Rate	On demand	35,644
Current portion of long term bank loans – secured	Hong Kong Interbank Offered Rate ("HIBOR")+1.60	2021-2022	162,558	HIBOR+1.60	2021	152,036
			198,612			187,680
Non-current						
Long term bank loans – secured	HIBOR+1.60	2022-2025	519,130	HIBOR+1.60	2022-2025	673,063
			519,130			673,063
			717,742			860,743

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

18. INTEREST-BEARING BANK BORROWINGS (CONTINUED)

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Analysed into:		
Bank loans repayable:		
Within one year or on demand	198,612	187,680
In the second year	389,338	173,402
In the third to fifth years, inclusive	129,792	499,661
	717,742	860,743

Notes:

- (a) As at 30 June 2021 (unaudited) and 31 December 2020 (audited), all bank borrowings are secured by the corporate guarantees of the Company and certain of its subsidiaries.
- (b) As at 30 June 2021 (unaudited), the Group's bank borrowings denominated in HK\$ and RMB amounted to HK\$681,688,000 and HK\$36,054,000, respectively. As at 31 December 2020 (audited), the Group's bank borrowings denominated in HK\$ and RMB amounted to HK\$825,099,000 and HK\$35,644,000, respectively.

19. SHARE CAPITAL

	30 June 2021 (Unaudited) US\$'000	31 December 2020 (Audited) US\$'000
Shares		
Issued and fully paid:		
959,577,000 (31 December 2020: 962,477,000) ordinary shares of US\$0.01 each	9,596	9,625
Equivalent to HK\$'000	74,367	74,592

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

19. SHARE CAPITAL (CONTINUED)

A summary of movements in the Company's share capital is as follows:

	Note	Number of shares in issue	Share capital HK\$'000	Treasury shares HK\$'000	Share premium HK\$'000	Total HK\$'000
At 1 January 2020 (audited)		981,646,000	76,078	(21,796)	614,924	669,206
2019 final dividend		—	—	—	(21,172)	(21,172)
Shares repurchased	(a)	—	—	(9,934)	—	(9,934)
Shares cancelled	(a)	(19,169,000)	(1,486)	28,624	(27,138)	—
At 31 December 2020 and 1 January 2021 (audited)		962,477,000	74,592	(3,106)	566,614	638,100
2020 final dividend		—	—	—	(66,986)	(66,986)
Shares repurchased	(b)	—	—	(7,896)	—	(7,896)
Shares cancelled	(b)	(2,900,000)	(225)	3,962	(3,737)	—
At 30 June 2021 (unaudited)		959,577,000	74,367	(7,040)	495,891	563,218

Note:

- (a) On 28 May 2020, the Company's shareholders granted a general mandate (the "**Repurchase Mandate 2020**") to the directors of the Company to repurchase shares of the Company at the annual general meeting. Pursuant to the Repurchase Mandate 2020, the Company is allowed to repurchase up to 96,247,700 shares, being 10% of the total number of issued shares of the Company as at the date of the general meeting, on the Hong Kong Stock Exchange.

For the year ended 31 December 2020, the Company repurchased 6,850,000 of its ordinary shares on the Hong Kong Stock Exchange at an aggregate consideration of HK\$9,934,000 (before expenses). Out of 6,850,000 repurchased ordinary shares, 4,600,000 ordinary shares of HK\$6,867,000 (before expenses), together with 14,569,000 ordinary shares of HK\$21,757,000 (before expenses) repurchased during the year ended 31 December 2019, were cancelled during the year ended 31 December 2020, while the remaining 2,250,000 repurchased ordinary shares of HK\$3,067,000 (before expenses) were recognised as treasury shares as at 31 December 2020.

- (b) On 27 May 2021, the Company's shareholders granted a general mandate (the "**Repurchase Mandate 2021**") to the directors of the Company to repurchase shares of the Company at the annual general meeting. Pursuant to the Repurchase Mandate 2021, the Company is allowed to repurchase up to 95,957,700 shares, being 10% of the total number of issued shares of the Company as at the date of the general meeting, on the Hong Kong Stock Exchange.

For the six months ended 30 June 2021, the Company repurchased 3,286,000 of its ordinary shares on the Hong Kong Stock Exchange at an aggregate consideration of HK\$7,896,000 (before expenses). Out of 3,286,000 repurchased ordinary shares, 650,000 ordinary shares of HK\$895,000 (before expenses), together with 2,250,000 ordinary shares of HK\$3,067,000 (before expenses) repurchased during the year ended 31 December 2020, were cancelled during the six months ended 30 June 2021, while the remaining 2,636,000 repurchased ordinary shares of HK\$7,001,000 (before expenses) were recognised as treasury shares as at 30 June 2021.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

20. PRE-IPO RESTRICTED SHARE UNIT SCHEME

The Company operates a pre-IPO restricted share unit scheme (the "**Pre-IPO RSU Scheme**") for the purpose of providing incentives and rewards to eligible participants who contribute to the success of the Group's operations. The Pre-IPO RSU Scheme shall be subject to the administration of the board of directors (the "**Board**") and the Board may delegate the authority to an award committee (the "**Award Committee**"). Eligible participants of the Pre-IPO RSU Scheme include the Company's directors, other employees of the Group and any other person selected by the Board or the Award Committee from time to time. The Pre-IPO RSU Scheme became effective on 19 June 2015 and, unless otherwise cancelled or amended, will remain in force for 10 years from that date.

Unless otherwise duly approved by the shareholders, the total number of shares underlying restricted share units (the "**RSUs**") under the Pre-IPO RSU Scheme shall not exceed 5,131,000, and following the capitalisation issue, has adjusted to 8,149,038 and representing approximately 0.81% of the enlarged issued share capital of the Company immediately following the completion of the capitalisation issue and the global offering.

The offer of a grant of RSUs may be accepted within the time period and in a manner prescribed in the grant letter. The Board or the Award Committee (if authority is delegated) has the sole discretion to determine the vesting schedule and vesting criteria (if any) for any grant of award(s) to any grantee, which may also be adjusted and re-determined by the Board or the Award Committee from time to time.

RSUs do not confer rights on the holders to dividends or to vote at shareholders' meetings.

21. CONTINGENT LIABILITIES

The Group had no significant contingent liabilities as at 30 June 2021 and 31 December 2020.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

22. COMMITMENTS

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Contracted, but not provided for:		
Leasehold improvement	4,143	2,407
Land and buildings	82,388	84,521
	86,531	86,928

An investment agreement was entered into between Modern Dental Laboratory Company Limited and Dongguan Songshan Lake High-tech Industrial Development Zone Management Committee regarding an investment of not less than RMB246,000,000 (equivalent to HK\$295,645,000) for the acquisition of land, construction and renovation of a factory in the Songshan Lake High-tech Industrial Development Zone. As at 30 June 2021, the Group has paid approximately RMB156,597,000 (equivalent to HK\$188,199,000) for the construction and renovation of a factory and approximately RMB18,839,000 (equivalent to HK\$22,641,000) for the acquisition of land, respectively, and the remaining commitment was approximately RMB70,564,000 (equivalent to HK\$84,805,000).

Except for such agreements, the Group did not have any other significant commitments as at 30 June 2021 and 31 December 2020.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

23. RELATED PARTY TRANSACTIONS

(1) TRANSACTIONS WITH RELATED PARTIES

In addition to the transactions detailed elsewhere in these financial statements, the Group had the following transactions with related parties during the period:

	Notes	Six months ended 30 June	
		2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
Payment of lease liabilities to Most Wealth International Limited	(a)	1,728	1,944
Payment of lease liabilities to directors	(b)	81	606
Payment of lease liabilities to directors and an associate of a director	(c)	1,128	1,283
Payment of lease liabilities to an associate of a director	(d)	110	93
Payment of lease liabilities to an associate of a director	(e)	110	69
Payment of lease liabilities to an associate of a director	(f)	248	208
Training fee paid to ShenZhen Nanshan District Modern Denture Technology Training Centre	(g)	906	587
Sales of finished goods to Trident Dental Group Limited	(h)	159	153
Sales of finished goods to Kong Hong Holdings Limited	(i)	115	91
Sales of finished goods to Dr. William Cheung & Associates	(j)	56	39
Purchase of finished goods from an associate	(k)	3,734	—

Notes:

- (a) Most Wealth International Limited ("Most Wealth") is controlled by Mr. Chan Kwun Fung, Mr. Chan Kwun Pan and Mr. Ngai Shing Kin. The transactions with Most Wealth were made on prices and conditions as mutually agreed.
- (b) Rental fee was paid to Mr. Chan Kwun Fung and Mr. Chan Kwun Pan. The tenancy agreements were entered into on prices and conditions as mutually agreed.
- (c) Rental fee was paid to Mr. Chan Kwun Fung, Mr. Chan Kwun Pan and an associate ("Landlord C") of Mr. Ngai Shing Kin. The tenancy agreements were entered into on prices and conditions as mutually agreed.
- (d) Rental fee was paid to an associate ("Landlord B") of Mr. Chan Kwun Pan. The tenancy agreements were entered into on prices and conditions as mutually agreed.
- (e) Rental fee was paid to Landlord C. The tenancy agreements were entered into on prices and conditions as mutually agreed.
- (f) Rental fee was paid to an associate ("Landlord A") of Mr. Chan Kwun Fung. The tenancy agreements were entered into on prices and conditions as mutually agreed.
- (g) ShenZhen Nanshan District Modern Denture Technology Training Centre (the "Centre") and the Company has a common director, Mr. Ngai Shing Kin. The transactions with the Centre were made on prices and conditions as mutually agreed.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

23. RELATED PARTY TRANSACTIONS (CONTINUED)

(1) TRANSACTIONS WITH RELATED PARTIES (CONTINUED)

Notes: (continued)

- (h) Trident Dental Group Limited is ultimately 33.3% owned by Dr. Chan Ronald Yik Long. The transactions with Trident Dental Group Limited were made on prices and conditions as mutually agreed.
- (i) Kong Hong Holdings Limited is ultimately 40% owned by Dr. Chan Ronald Yik Long. The transactions with Kong Hong Holdings Limited were made on prices and conditions as mutually agreed.
- (j) Dr. William Cheung & Associates is ultimately 51% owned by Dr. Cheung Wai Man William. The transactions with Dr. William Cheung & Associates were made on prices and conditions as mutually agreed.
- (k) The cost of purchases from an associate was made at pre-determined prices agreed between the parties.

Mr. Chan Kwun Fung, Mr. Chan Kwun Pan, Mr. Ngai Shing Kin and Dr. Chan Ronald Yik Long are shareholders and directors of the Company. Dr. Cheung Wai Man William and Dr. Yau Ka Po are directors of the Company.

The related party transactions in respect of items (a), (b), (c), (d), (e), (f), (h), (i) and (j) above also constitute continuing connected transactions as defined in Chapter 14A of the Listing Rules.

(2) COMMITMENTS WITH RELATED PARTIES

- (a) For the purpose of operating the Company's business in Hong Kong, on 30 December 2020, Modern Dental Laboratory Company Limited ("**MDLCL**"), a wholly-owned subsidiary of the Company, entered into a tenancy agreement (the "**Tenancy Agreements I**") with Most Wealth International Limited, which is held as to 37.5%, 37.5% and 25% by Mr. Chan Kwun Fung and Mr. Chan Kwun Pan and by Mr. Ngai Shing Kin respectively. Pursuant to the Tenancy Agreement I, Most Wealth International Limited shall lease premises to MDLCL for a term of two years commencing from 1 January 2021 to 31 December 2022 at a monthly rent of HK\$288,000.
- (b) For the purposes of residential use, on 30 December 2020, Yangzhijin Dental Laboratory (Shenzhen) Company Limited ("**YZJSZ**"), a wholly-owned subsidiary of the Company, entered into a tenancy agreement (the "**Tenancy Agreements II**") with Mr. Chan Kwun Fung and Mr. Chan Kwun Pan and Landlord C. Pursuant to the Tenancy Agreements II, Mr. Chan Kwun Fung, Mr. Chan Kwun Pan and Landlord C shall lease premises to YZJSZ for a term of two years from 1 January 2021 to 31 December 2022 at a monthly rent of RMB119,006.64
- (c) For the purposes of residential use, on 30 December 2020, Modern Dental Laboratory (Shenzhen) Company Limited ("**MDLSZ**") entered into a tenancy agreement (the "**Tenancy Agreements III**") with Mr. Chan Kwun Fung and Mr. Chan Kwun Pan and Landlord C. Pursuant to the Tenancy Agreements III, Mr. Chan Kwun Fung, Mr. Chan Kwun Pan and Landlord C shall lease premises to MDLSZ for a term of two years from 1 January 2021 to 31 December 2022 at a monthly rent of RMB37,293.
- (d) For the purposes of residential use, on 30 December 2020, MDLSZ entered into a tenancy agreement (the "**Tenancy Agreement IV**") with Landlord B. Pursuant to the Tenancy Agreement IV, Landlord B shall lease premises to MDLSZ for a term of two years from 1 January 2021 to 31 December 2022 at a monthly rent of RMB15,280.
- (e) For the purposes of residential use, on 30 December 2020, MDLSZ entered into a tenancy agreement (the "**Tenancy Agreement V**") with Landlord C. Pursuant to the Tenancy Agreement V, Landlord C shall lease premises to MDLSZ for a term of two years from 1 January 2021 to 31 December 2022 at a monthly rent of RMB15,280.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

23. RELATED PARTY TRANSACTIONS (CONTINUED)

(2) COMMITMENTS WITH RELATED PARTIES (CONTINUED)

- (f) For the purposes of residential use, on 30 December 2020, MDLSZ entered into a tenancy agreement (the "**Tenancy Agreement VI**") with Landlord A. Pursuant to the Tenancy Agreement VI, Landlord A shall lease premises to MDLSZ for a term of two years from 1 January 2021 to 31 December 2022 at a monthly rent of RMB34,380.
- (g) For the purpose of operating the Company's business in Hong Kong, on 30 December 2020, MDLCL, entered into a tenancy agreement (the "**Tenancy Agreements VII**") with Mr. Chan Kwun Fung and Mr. Chan Kwun Pan. Pursuant to the Tenancy Agreements VII, Mr. Chan Kwun Fung and Mr. Chan Kwun Pan shall lease premises to MDLCL for a term of two years from 1 January 2021 to 31 December 2022 at a monthly rent of HK\$13,500.

In accordance with IFRS 16, which came into effect on leases entered into after 1 January 2019, the Group as lessee shall recognise a lease as a right-of-use asset and a lease liability. The right-of-use asset represents its right to use the underlying leased assets over the lease term and the lease liability represents its obligation to make lease payments.

As at 30 June 2021, right-of-use assets of approximately HK\$9,826,000 and lease liabilities of approximately HK\$9,868,000 related to the leases were recognised in interim condensed consolidated statement of financial position. During the six months ended 30 June 2021, depreciation of these right-of-use assets of approximately HK\$3,273,000 and finance costs on these lease liabilities of approximately HK\$172,000 were recognised in interim condensed consolidated income statement.

(3) BALANCES WITH RELATED PARTIES

As at 30 June 2021 and 31 December 2020, the Group's balances with related parties were as follows:

	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Due from related parties (note 14):		
Trident Dental Group Limited	—	152
Kong Hong Holdings Limited	—	76
Dr. William Cheung & Associates	—	12
	—	240
Due to a related party (note 17):		
ShenZhen Nanshan District Modern Denture Technology Training Centre	5	10

The Group's balances with its related parties as at the end of the reporting period are unsecured, non-interest-bearing and has no fixed terms of repayment.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

23. RELATED PARTY TRANSACTIONS (CONTINUED)

(4) COMPENSATION OF KEY MANAGEMENT PERSONNEL OF THE GROUP

	Six months ended 30 June	
	2021 (Unaudited) HK\$'000	2020 (Unaudited) HK\$'000
Short term employee benefits	21,243	15,380
Post-employment benefits	1,014	941
Total compensation paid to key management personnel	22,257	16,321

Save as disclosed above and elsewhere in the interim condensed consolidated financial statements, the Group did not have other related party transactions during the period.

24. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those with carrying amounts that reasonably approximate to fair values, are as follows:

	Carrying amounts		Fair values	
	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000	30 June 2021 (Unaudited) HK\$'000	31 December 2020 (Audited) HK\$'000
Financial liabilities				
Interest-bearing bank borrowings	717,742	860,743	717,742	860,743

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, trade receivables, trade payables, financial assets included in deposits and other receivables, amounts due from/to related parties, an amount due from/to an associate, an amount due to a non-controlling shareholder, and financial liabilities included in other payables and accruals approximate to their carrying amounts and accordingly no disclosure of the fair value of these items is presented.

The Group's finance department headed by the chief financial officer is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

24. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (CONTINUED)

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

The fair values of interest-bearing bank borrowings have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The Group's own non-performance risk for interest-bearing bank borrowings as at 30 June 2021 was assessed to be insignificant.

FAIR VALUE HIERARCHY

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

LIABILITIES FOR WHICH FAIR VALUES ARE DISCLOSED:

As at 30 June 2021

	Fair value measurement using			Total (Unaudited) HK\$'000
	Quoted prices in active markets (Level 1) (Unaudited) HK\$'000	Significant observable Inputs (Level 2) (Unaudited) HK\$'000	Significant unobservable inputs (Level 3) (Unaudited) HK\$'000	
Interest-bearing bank borrowings	—	717,742	—	717,742

As at 31 December 2020

	Fair value measurement using			Total (Audited) HK\$'000
	Quoted prices in active markets (Level 1) (Audited) HK\$'000	Significant observable Inputs (Level 2) (Audited) HK\$'000	Significant unobservable inputs (Level 3) (Audited) HK\$'000	
Interest-bearing bank borrowings	—	860,743	—	860,743

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

30 June 2021

25. EVENTS AFTER THE REPORTING PERIOD

- (i) Subsequent to the end of the reporting period, 2,636,000 ordinary shares of approximately HK\$7,001,000 (before expenses) repurchased in six months ended 30 June 2021 were cancelled in July 2021.
- (ii) On 9 July 2021, MDPCH Pty Ltd, a wholly owned subsidiary of the Company, entered into a share purchase agreement with Panagiotis (Peter) Nouris and Alexander Petrators, to acquire a 100% equity interest of Swift Dental Laboratory ("**Swift**") at a consideration of AUD800,000 and a contingent consideration of AUD500,000. Swift is principally engaged in provision of dentures in Austrian market. The acquisition was completed on 9 July 2021. The acquisition will provide the Group with an important foundation to build on its existing Australian-made denture work to further expand the Group's product offering and services to its existing clients.

Save as disclosed above, the Group does not have other significant subsequent event as at the date of these financial statements.

26. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements were approved and authorised for issue by the board of directors on 30 August 2021.

CORPORATE INFORMATION

PLACE OF INCORPORATION

Cayman Islands

BOARD OF DIRECTORS

EXECUTIVE DIRECTORS

Dr. CHAN Ronald Yik Long (*Chairman*)
 Mr. NGAI Chi Ho Alwin
(Vice-Chairman and Chief Operating Officer)
 Mr. NGAI Shing Kin (*Chief Executive Officer*)
 Ms. CHAN Yik Yu (*Chief Marketing Officer*)
 Mr. CHAN Kwun Fung
 Mr. CHAN Kwun Pan
 Mr. CHAN Chi Yuen

INDEPENDENT NON-EXECUTIVE DIRECTORS

Dr. CHEUNG Wai Bun Charles, J.P.
 Dr. CHAN Yue Kwong Michael
 Dr. CHEUNG Wai Man William
 Dr. YAU Ka Po

BOARD COMMITTEES

AUDIT COMMITTEE

Dr. CHEUNG Wai Bun Charles, J.P. (*Chairman*)
 Dr. CHAN Yue Kwong Michael
 Dr. YAU Ka Po

REMUNERATION COMMITTEE

Dr. CHEUNG Wai Man William (*Chairman*)
 Dr. CHEUNG Wai Bun Charles, J.P.
 Mr. NGAI Shing Kin
 Ms. CHAN Yik Yu
 Dr. YAU Ka Po

NOMINATION COMMITTEE

Dr. CHAN Yue Kwong Michael (*Chairman*)
 Dr. CHEUNG Wai Bun Charles, J.P.
 Dr. CHEUNG Wai Man William
 Mr. NGAI Chi Ho Alwin
 Dr. CHAN Ronald Yik Long

COMPANY SECRETARY

Mr. KWAN Ngai Kit

AUTHORISED REPRESENTATIVES

Mr. NGAI Shing Kin
 Mr. KWAN Ngai Kit

AUDITOR

Ernst & Young

REGISTERED OFFICE

Cricket Square, Hutchins Drive
 P.O. Box 2681
 Grand Cayman KY1-1111
 Cayman Islands

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 01-07, 09-16
 17/F., CEO Tower
 77 Wing Hong Street
 Cheung Sha Wan
 Kowloon, Hong Kong

CORPORATE INFORMATION

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE IN THE CAYMAN ISLANDS

Conyers Trust Company (Cayman) Limited
Cricket Square, Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Tricor Investor Services Limited
Level 54, Hopewell Centre
183 Queen's Road East
Hong Kong

PRINCIPAL BANKERS

The Hongkong and Shanghai Banking Corporation Limited
Bank of China (Hong Kong) Limited
Chiyu Banking Corporation Limited
China Construction Bank (Asia) Corporation Limited

COMPANY WEBSITE

www.moderndentalgp.com

STOCK CODE

3600